MAT2A and cancer: Studies show that methionine adenosyltransferase 2A (MAT2A) inhibitors induce synthetic lethality of MTAP-deleted cancer, especially in combination with taxanes and gemcitabine (100), which demonstrate a potential to treat MPM of the nuclear DAMPs subtype.